GlassScriptPhysician profile
Bridget Kennedy
NPI 1518685395
$1,656.35
in general payments reported to CMS, 2019-2025
24 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $408 · 2024: $604 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $373.48 | 2022-2025 | |
| Abbvie INC. | $263.41 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $153.07 | 2023-2025 | Ultomiris, Soliris |
| Impel Pharmaceuticals INC. | $116.47 | 2023 | Trudhesa |
| Ucb, INC. | $100.40 | 2022-2025 | Zilbrysq, Briviact |
| Sk Life Science, INC. | $62.83 | 2022-2024 | |
| Argenx US, INC. | $62.27 | 2023-2024 | Vyvgart Hytrulo |
| Genentech USA, INC. | $53.13 | 2022-2025 | Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $51.01 | 2024-2025 | |
| Harmony Biosciences LLC | $46.39 | 2023 | Wakix |
| Mdd US Operations, LLC | $41.47 | 2022 | |
| Biogen, INC. | $40.94 | 2022-2025 | Tysabri, Vumerity |
| Amgen INC. | $37.48 | 2025 | Uplizna |
| Lundbeck LLC | $33.39 | 2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.90 | 2025 | Hyqvia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.80 | 2024 | Emgality |
| Boston Scientific Corporation | $25.00 | 2023 | Watchman Access System |
| Scilex Pharmaceuticals INC. | $24.08 | 2024 | |
| Impel Pharmaceuticals LLC | $23.64 | 2025 | Trudhesa |
| Celgene Corporation | $22.67 | 2025 | Zeposia |
| Pfizer INC. | $22.04 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $18.71 | 2023 | Iovera, Zilretta, Exparel |
| Teva Pharmaceuticals USA, INC. | $17.94 | 2025 | Austedo Xr |
| Acorda Therapeutics, INC | $13.83 | 2024 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.